PH12019501514A1 - Integrin antagonists - Google Patents

Integrin antagonists

Info

Publication number
PH12019501514A1
PH12019501514A1 PH12019501514A PH12019501514A PH12019501514A1 PH 12019501514 A1 PH12019501514 A1 PH 12019501514A1 PH 12019501514 A PH12019501514 A PH 12019501514A PH 12019501514 A PH12019501514 A PH 12019501514A PH 12019501514 A1 PH12019501514 A1 PH 12019501514A1
Authority
PH
Philippines
Prior art keywords
pharmaceutical agents
integrins
compounds
integrin antagonists
avá8
Prior art date
Application number
PH12019501514A
Other languages
English (en)
Inventor
Peter G Ruminski
David W Griggs
Scott Seiwert
Original Assignee
Univ Saint Louis
Indalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saint Louis, Indalo Therapeutics Inc filed Critical Univ Saint Louis
Publication of PH12019501514A1 publication Critical patent/PH12019501514A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PH12019501514A 2016-12-29 2019-06-27 Integrin antagonists PH12019501514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440253P 2016-12-29 2016-12-29
US201762471882P 2017-03-15 2017-03-15
PCT/US2017/068801 WO2018132268A1 (en) 2016-12-29 2017-12-28 Integrin antagonists

Publications (1)

Publication Number Publication Date
PH12019501514A1 true PH12019501514A1 (en) 2020-09-14

Family

ID=62840040

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019501514A PH12019501514A1 (en) 2016-12-29 2019-06-27 Integrin antagonists

Country Status (14)

Country Link
US (1) US11306084B2 (enExample)
EP (1) EP3562826A4 (enExample)
JP (1) JP2020504120A (enExample)
KR (1) KR20190100232A (enExample)
CN (1) CN110177787A (enExample)
AU (1) AU2017393297A1 (enExample)
BR (1) BR112019012515A2 (enExample)
CA (1) CA3045491A1 (enExample)
CO (1) CO2019007023A2 (enExample)
IL (1) IL267686A (enExample)
MX (1) MX2019007797A (enExample)
PH (1) PH12019501514A1 (enExample)
RU (1) RU2019116820A (enExample)
WO (1) WO2018132268A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
US20240245682A1 (en) * 2022-12-27 2024-07-25 Pliant Therapeutics, Inc. Alpha-v-beta-8 integrin inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269876A1 (en) * 2000-06-15 2001-12-24 Mark Laurence Boys Heteroarylalkanoic acids as integrin receptor antagonists
BR0316875A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos de pirazol como derivados antagonistas receptores da integrina, sua composição farmacêutica e respectivo uso
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
EP1572690A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
US8716226B2 (en) * 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
IN2015DN00099A (enExample) * 2012-07-18 2015-05-29 Univ Saint Louis
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
CA3042707A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as .alpha.v integrin inhibitors
KR102506327B1 (ko) 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 αV 인테그린 길항제로서의 인다졸 유도체
JP7128811B2 (ja) 2016-11-08 2022-08-31 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン
LT3538528T (lt) 2016-11-08 2021-03-10 Bristol-Myers Squibb Company Pirolo amidai, kaip alfa v integrino inhibitoriai
CN110167934B (zh) 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US20210284638A1 (en) 2018-07-03 2021-09-16 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS

Also Published As

Publication number Publication date
CA3045491A1 (en) 2018-07-19
BR112019012515A2 (pt) 2019-11-19
CO2019007023A2 (es) 2019-07-31
EP3562826A1 (en) 2019-11-06
IL267686A (en) 2019-08-29
US20190345155A1 (en) 2019-11-14
EP3562826A4 (en) 2020-08-26
WO2018132268A8 (en) 2019-06-20
KR20190100232A (ko) 2019-08-28
MX2019007797A (es) 2019-10-21
WO2018132268A1 (en) 2018-07-19
RU2019116820A (ru) 2021-01-29
US11306084B2 (en) 2022-04-19
CN110177787A (zh) 2019-08-27
JP2020504120A (ja) 2020-02-06
AU2017393297A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
PH12019501514A1 (en) Integrin antagonists
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12017502107A1 (en) Triazole agonists of the apj receptor
MX376465B (es) Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret.
MX384087B (es) Piperidinas como inhibidores de menina.
WO2016023014A3 (en) Uses of salt-inducible kinase (sik) inhibitors
MY192059A (en) Heterocyclic amides as kinase inhibitors
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2017012613A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MY193765A (en) Sulfonylureas and related compounds and use of same
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
WO2017050791A8 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2019008435A (es) Inhibidores selectivos de jak1.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MY185491A (en) Macrocylic pyrimidine derivatives
PH12018501362A1 (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
SA518392179B1 (ar) مركبات من مضاد لمستقبل سوماتوستاتين وطرق استخدامها